Viralytics Ltd reveals positive cancer immunotherapy results
10:00 14 Nov 2016
Viralytics Ltd (ASX:VLA) has received positive clinical results from the ongoing Phase 1b clinical trial of its cancer immunotherapy drug, CAVATAK, in combination checkpoint inhibitor KEYTRUDA.
http://www.*.com.au/thumbs/upload/News/Image/2016_11/757z468_1-shutterstock_233501644.jpg
Viralytics Ltd reveals positive cancer immunotherapy results
CAVATAK is a novel cancer immunotherapy based on a proprietary cold virus that has been shown to preferentially infect and attack cancer cells.
The Phase 1b trial is designed to evaluate the safety and tolerability of CAVATAK in combination with KEYTRUDA, in 30 patients with advanced melanoma.
According to the preliminary data from the first 10 patients evaluable for best overall tumour response assessment, a disease control rate of 100% was demonstrated.
The response rates and side event profile of this immunotherapy combination compare favourably with other combination clinical trials in melanoma.
The increased activity of the drug in difficult-to treat, late-stage patients with a low rate of adverse events signals the potential to improve the treatment of melanoma and other cancer types.
Viralytics is well funded with $42 million in cash as at 30 September 2016.
The company’s share price has doubled since the beginning of 2016, last trading at $1.32.
